Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma
Shelly Kalaora(Weizmann Institute of Science), Yardena Samuels(Weizmann Institute of Science), Michal Alon(Weizmann Institute of Science), Polina Greenberg(Weizmann Institute of Science), Yishai Levin(Weizmann Institute of Science), Eilon Barnea(Technion – Israel Institute of Technology), Gitit Bar Eli(Weizmann Institute of Science), Joo Sang Lee(National Institutes of Health), Ronen Levy(Weizmann Institute of Science), Eytan Ruppin(National Institutes of Health), Sushant Patkar(National Institutes of Health), Steven A. Rosenberg(National Cancer Institute), Aviyah Peri(Weizmann Institute of Science), Michal Lotem(Hadassah Medical Center), Arie Admon(Technion – Israel Institute of Technology), Roni Oren(Weizmann Institute of Science), Gal Yagel(Weizmann Institute of Science), Lital Bitton(Weizmann Institute of Science)
Cited by 156
Related Papers
Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
|Journal of Clinical Oncology|2008|1.3k
IL-2: The First Effective Immunotherapy for Human Cancer
|The Journal of Immunology|2014|1.3k
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
|Journal of Clinical Investigation|2014|1.1k
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
|Nature Medicine|2018|813